The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）
This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.
Oligo-metastatic Stage IV Non-small Cell Lung Cancer
RADIATION: concurrent chemoradiotherapy|DRUG: Docetaxel|DRUG: pemetrexed|DRUG: Cisplatin
short-term effects（The response rate，RR）, Response Evaluation Criteria In Solid Tumors (RECIST), 3 months after the end of the treatment
PFS（progression-free survival）, up to 3 years|Quality of life (QOL), Quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Trial Outcome Index (FACT-TOI) and lung cancer subscale (LCS), up to 3 years|esophagitis and pneumonitis, Grade 3-5 esophagitis and pneumonitis adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0, up to 3 years|Other grade 3-5 adverse events, Other grade 3-5 adverse events as assessed by NCI CTCAE v3.0, up to 3 years
This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.